Related Experiment Video

Updated: Jun 5, 2026

Rapid Screening of HIV Reverse Transcriptase and Integrase Inhibitors
05:46

Rapid Screening of HIV Reverse Transcriptase and Integrase Inhibitors

Published on: April 9, 2014

Comparative Effectiveness and Toxicity of Statins Among HIV-Infected Patients

Sudershan Singh1, James H Willig, Michael J Mugavero

  • 1Department of Medicine, University of Washington, Seattle, WA 98104, USA.

Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America
|December 30, 2010
PubMed

Insights

Atorvastatin and rosuvastatin are more effective than pravastatin for lowering cholesterol in HIV patients. These statins achieved greater lipid reductions with similar toxicity rates, making them preferable choices.

Area of Science:

  • Cardiology
  • Infectious Diseases
  • Pharmacology

Background:

  • Dyslipidemia is prevalent in human immunodeficiency virus (HIV)-infected patients.
  • 3-hydroxy-3-methylglutaryl coenzyme A (HMG CoA) reductase inhibitors (statins) are common treatments for dyslipidemia.
  • Comparative effectiveness of statins in HIV patients is not well-established.

Purpose of the Study:

  • To compare the effectiveness and toxicity of different statins in HIV-infected patients.
  • To evaluate lipid level changes and achievement of National Cholesterol Education Program (NCEP) goals.
  • To assess statin-associated toxicity rates in this population.

Main Methods:

  • Retrospective cohort study of 700 HIV-infected patients initiating statin therapy.
  • Primary outcome: change in lipid levels (total cholesterol, LDL-C, non-HDL-C).
  • Secondary outcomes: NCEP goal attainment and toxicity rates; linear regression and propensity score analyses were used.

Main Results:

  • Atorvastatin and rosuvastatin showed significantly greater reductions in total cholesterol, LDL-C, and non-HDL-C compared to pravastatin.
  • Higher likelihood of reaching LDL-C goals with rosuvastatin and atorvastatin versus pravastatin.
  • Similar toxicity rates observed across atorvastatin (7.3%), pravastatin (6.1%), and rosuvastatin (5.3%).

Conclusions:

  • Atorvastatin and rosuvastatin are recommended over pravastatin for managing dyslipidemia in HIV-infected patients.
  • These statins offer superior lipid-lowering effects with comparable safety profiles.
  • Findings support informed statin selection for improved cardiovascular risk management in HIV care.
Abstract

More Related Videos

Oral Combinational Antiretroviral Treatment in HIV-1 Infected Humanized Mice06:07

Oral Combinational Antiretroviral Treatment in HIV-1 Infected Humanized Mice

Published on: October 6, 2022

Related Concept Videos

Lipid-Lowering Drugs: Statins and Miscellaneous Agents01:20

Lipid-Lowering Drugs: Statins and Miscellaneous Agents

Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...
Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test01:22

Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test

In clinical practice, the direct measurement of hepatic blood flow to evaluate liver function presents significant challenges due to the intricate and specialized nature of the necessary techniques. Consequently, healthcare professionals often rely on empirical estimates derived from thorough patient examinations and liver function tests to gauge liver health. Among the tools at their disposal, the Child–Pugh and MELD scoring systems stand out for their ability to categorize and assess the...
Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment01:08

Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment

Hepatic impairment, characterized by decreased liver function, does not uniformly mandate adjustments in drug dosage. Whether dosage modifications are necessary depends on various factors related to the drug's metabolism and elimination pathways. If a drug is primarily excreted via the kidneys and bypasses significant hepatic processing, if it undergoes minimal metabolic transformation in the liver, or if it is volatile and primarily expelled through the lungs, dose adjustments may not be...
Retrovirus Life Cycles01:10

Retrovirus Life Cycles

Retroviruses have a single-stranded RNA genome that undergoes a special form of replication. Once the retrovirus has entered the host cell, an enzyme called reverse transcriptase synthesizes double-stranded DNA from the retroviral RNA genome. This DNA copy of the genome is then integrated into the host’s genome inside the nucleus via an enzyme called integrase. Consequently, the retroviral genome is transcribed into RNA whenever the host’s genome is transcribed, allowing the retrovirus to...
Inhibitors of Viral Protein Synthesis01:30

Inhibitors of Viral Protein Synthesis

Protein synthesis is indispensable for viral replication, as viruses lack the cellular machinery required for this process and must hijack the host's translational apparatus. In response, host cells deploy a critical innate immune defense involving interferons, specialized cytokines that play a central role in inhibiting viral propagation.Upon viral detection, infected cells release interferons that bind to receptors on adjacent uninfected cells, activating the JAK-STAT signaling pathway and...
Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow01:26

Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow

Chronic liver disease significantly impacts drug metabolism due to alterations in hepatic blood flow and enzyme accessibility. This disruption affects the body's pharmacokinetics—the movement and processing of drugs within the system. Key enzymes crucial for metabolizing medications become less accessible, changing how drugs are processed and utilized. Furthermore, liver disease influences the synthesis of plasma proteins, such as albumin and globulins, which play critical roles in drug binding...